The results showed that CRC patients with high expression of CMTM6 in CD163+ M2 macrophages had the greatest benefit from PD-1/PD-L1 inhibitors, with response rates of 71.4 and 66.7% in dMMR CRC patients and 75% in pMMR CRC patients. The gene discussed is CD163; the disease is colorectal carcinoma.